Investing Profile

Nassim Usman

InvestorVC
Entrepreneur in Residence & Venture Partner at Ribozyme Pharmaceuticals
morgenthaler.comSouth San Francisco, California
Photo of Nassim Usman, Ribozyme Pharmaceuticals

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Massachusetts Institute of Technology Network
393 CONNECTIONS
McGill University Network
108 CONNECTIONS
McGill University Network
108 CONNECTIONS
cb
$100K - $5.0M
$1.5M
6
CompanyStageDateRound SizeTotal Raised
Principia Biopharma
Series BAug 2015$15M
Series BApr 2014$50M
Series AOct 2012$13M
$78M
Co-investors: Peter Thompson (OrbiMed), Mike Dybbs (Samsara BioCapital), Simeon J. George (SR One)
Gyre Therapeutics
Post Ipo EquityApr 2013$5M
Post Ipo EquitySep 2012$13M
Post Ipo EquityDec 2008$40M
$88M
Co-investors: Ralph (Chris) Christoffersen (Lightstone Ventures), Asish Xavier (Johnson & Johnson Innovation)
COO & CSO Sirna TherapeuticsPresent
VP R&D & CSO Ribozyme PharmaceuticalsPresent
Postdoctoral Fellow, Staff Scientist Ribozyme PharmaceuticalsPresent
Member Of The Supervisory Board Atugen AGPresent
Member Board Of Directors Principia BiopharmaPresent
Member Board Of Directors Mosaic BiosciencesPresent
Executive Chair Ribozyme PharmaceuticalsPresent
Member Board of Directors Ribozyme PharmaceuticalsPresent
President & CEO, Member Board of Directors Catalyst BiosciencesPresent
Entrepreneur in Residence & Venture Partner Ribozyme PharmaceuticalsPresent
President & Chief Executive Officer Totus MedicinesPresent
Massachusetts Institute of Technology Fellow & Staff Scientist Biology & Chemistry
McGill University Bachelor of Science (BSc), Doctor of Philosophy (Ph.D.) Organic Chemistry
McGill University Bachelor of Science (BSc) Doctor of Philosophy (Ph.D.), Organic Chemistry